TickerFacts.

Prime Medicine, Inc. (PRME): Shareholders' Equity

Annual figures by period end, from SEC filings.

$120.87M
As of 2025-12-31
$39.81M
As of 2026-06-30
-27.4%
3-year compound annual growth
n/m
5-year compound annual growth
$316.27M2020-12-31: $2.34M2021-12-31: -$156.24M2022-12-31: $316.27M2023-12-31: $133.07M2024-12-31: $153.15M2025-12-31: $120.87M$120.87M
2020-12-31 Shareholders' Equity (USD) 2025-12-31
Period endedShareholders' EquityChange YoYSource filing
2025-12-31$120.87M-21.1%2026-03-03, Balance as of period end
2024-12-31$153.15M+15.1%2026-03-03, Balance as of period end
2023-12-31$133.07M-57.9%2025-02-28, Balance as of period end
2022-12-31$316.27Mn/m2024-03-01, Balance as of period end
2021-12-31-$156.24Mn/m2023-03-09, Balance as of period end
2020-12-31$2.34Mn/a2023-03-09, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShareholders' EquityChange YoY
Prime Medicine, Inc. (PRME)2025-12-31$120.87M-21.1%
Ocugen, Inc. (OCGN)2025-12-31-$12.17Mn/m
Zeo ScientifiX, Inc. (ZEOX)2025-10-31-$1.42Mn/m
CG Oncology, Inc. (CGON)2025-12-31$752.60M+2.6%
DBV Technologies S.A. (DBVT)2025-12-31$168.77M+516.2%
CRISPR Therapeutics AG (CRSP)2025-12-31$1.92B-0.5%
Surrozen, Inc. (SRZN)2025-12-31-$187.76Mn/m
Fate Therapeutics Inc (FATE)2025-12-31$207.18M-35.0%
Dyadic International Inc (DYAI)2025-12-31$1.23M-50.1%

Compare PRME, OCGN, ZEOX, CGON side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗